AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)
3.315 USD
-0.485 12.763%Sponsored Reports
Loading...
| Previous Close (in USD) | 3.8 |
|---|---|
| Change | -0.485 12.763% |
| 52 W H/L (in USD) | 16.745/4.970 |
| EBITDA (in USD) | -349.545M |
| PE Ratio | -- |
| Volume | 26750673 |
| Diluted Eps TTM | -1.63 |
| Total Assets (in USD) | 653.699M |
|---|---|
| Total Liabilities (in USD) | 190.263M |
| Revenue TTM (in USD) | 46.235M |
| Cash (in USD) | 394.796M |
| Market Cap (in USD) | 2,177.002 M |
| Revenue Per Share TTM | 0.211 |
| Gross Profit TTM (in USD) | -164.128M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
41 South Rio Grande Street, Salt Lake City, UT, United States, 84101
385 269 0203
Employees: 500
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Christopher C. Gibson Ph.D. | Co-Founder, CEO & Director | 1983 |
| 2. | Ms. Tina Marriott Larson | COO & Pres | 1975 |
| 3. | Dr. Blake C. Borgeson Ph.D. | Co-Founder & Director | 1982 |
| 4. | Dr. Michael Secora Ph.D. | Chief Financial Officer | 1983 |
| 5. | Dr. Shafique Virani M.D. | Interim Chief Medical Officer & Chief Bus. Officer | 1971 |
| 6. | Kevin Leggat | VP of Fin. & Accounting | NA |
| 7. | Mr. Benjamin Mabey M.S. | Chief Technology Officer | 1983 |
| 8. | Mr. Jared Allenbach | Sr. Director of Investor Relations | NA |
| 9. | Ms. Louisa Daniels J.D., M.B.A. | Chief Legal Officer & Gen. Counsel | 1958 |
| 10. | Mr. Ryan Kelly | Chief Communications Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.790 1.806% | 44.05 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.694 1.570% | 43.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+5.090 1.152% | 445.605 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+6.720 1.069% | 632.26 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -239.476M | -186.479M | -87.006M | -61.879M |
| Minority Interest | - | - | - | - |
| Net Income | -239.421M | -178.074M | -87.882M | -62.525M |
| Selling General Administrative | 81.599M | 57.682M | 25.258M | 18.951M |
| Gross Profit | -8.594M | 10M | 3.413M | 1.711M |
| Reconciled Depreciation | 11.756M | 8.405M | 4.442M | 3.543M |
| Ebit | -257.483M | -191.18M | -84.615M | -62.441M |
| Ebitda | -245.727M | -182.775M | -80.321M | -58.2M |
| Depreciation And Amortization | 11.756M | 8.405M | 4.294M | 4.241M |
| Operating Income | -245.727M | -182.775M | -84.615M | -62.441M |
| Other Operating Expenses | 285.408M | 192.775M | 88.028M | 64.152M |
| Interest Expense | 0.055M | 2.952M | 1.36M | 0.635M |
| Tax Provision | - | - | - | - |
| Interest Income | 6.254M | 0.073M | 0.336M | 1.741M |
| Net Interest Income | 6.199M | -2.879M | -1.024M | 1.106M |
| Income Tax Expense | -0.055M | -8.405M | 0.876M | 0.646M |
| Total Revenue | 39.681M | 10M | 3.413M | 1.711M |
| Total Operating Expenses | 237.133M | 192.775M | 88.028M | 64.152M |
| Cost Of Revenue | 48.275M | - | - | - |
| Total Other Income Expense Net | 6.251M | -3.704M | -2.391M | 0.562M |
| Net Income From Continuing Ops | -239.476M | -186.479M | -87.006M | -61.879M |
| Net Income Applicable To Common Shares | -239.476M | -186.479M | -87.006M | -61.879M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 653.699M | 701.288M | 610.345M | 298.585M | 101.431M |
| Intangible Assets | 36.443M | 1.306M | 1.385M | 2.49M | - |
| Other Current Assets | 40.247M | 15.869M | 7.514M | 2.155M | 1.076M |
| Total Liab | 190.263M | 215.482M | 67.407M | 504.874M | 225.696M |
| Total Stockholder Equity | 463.436M | 485.806M | 542.938M | -206.289M | -124.265M |
| Other Current Liab | 46.635M | 32.904M | 32.333M | 10.485M | 4.879M |
| Common Stock | 0.002M | 0.002M | 0.002M | - | - |
| Capital Stock | 0.002M | 0.002M | 0.002M | 0M | 0M |
| Retained Earnings | -967.622M | -639.556M | -400.08M | -213.601M | -126.595M |
| Good Will | 52.056M | 0.801M | 0.801M | - | - |
| Other Assets | 0M | 7.92M | 8.716M | 0.65M | 0.663M |
| Cash | 394.796M | 549.912M | 285.116M | 262.126M | 69.883M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 93.171M | 100.265M | 46.658M | 23.099M | 6.684M |
| Current Deferred Revenue | 36.426M | 56.726M | 10M | 10M | - |
| Net Debt | -344.124M | -498.907M | -273.638M | -246.464M | -53.714M |
| Short Term Debt | 6.157M | 6.049M | 1.506M | 1.54M | 0.544M |
| Short Long Term Debt | 0.041M | 0.097M | 0.09M | 1.073M | 0.077M |
| Short Long Term Debt Total | 50.672M | 51.005M | 11.478M | 15.662M | 16.169M |
| Other Stockholder Equity | 1431.056M | 1125.36M | 332.797M | 7.312M | 2.33M |
| Property Plant Equipment | - | 121.447M | 64.725M | 25.967M | 24.37M |
| Total Current Assets | 438.137M | 569.814M | 534.718M | 269.478M | 76.398M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | 0M | 231.446M | - | - |
| Net Receivables | 3.094M | 2.753M | 9.09M | 0.156M | 0.151M |
| Long Term Debt | 1.101M | 0.536M | 0.633M | 11.414M | 12.418M |
| Inventory | -3.094M | 1.28M | 1.552M | 5.041M | 5.288M |
| Accounts Payable | 3.953M | 4.586M | 2.819M | 1.074M | 1.261M |
| Accumulated Other Comprehensive Income | 0M | - | -0.126M | -9.962M | -5.715M |
| Non Currrent Assets Other | 0.261M | 7.92M | 8.716M | 0.65M | 0.663M |
| Non Current Assets Total | 215.562M | 131.474M | 75.627M | 29.107M | 25.033M |
| Capital Lease Obligations | 49.53M | 50.372M | 10.755M | 3.175M | 3.674M |
| Long Term Debt Total | - | - | 0.633M | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | 193.249M | -231.946M | -8.74M | -3.91M |
| Total Cashflows From Investing Activities | 193.249M | -271.744M | -8.74M | -3.91M |
| Total Cash From Financing Activities | 154.345M | 458.54M | 246.135M | 120.41M |
| Net Income | -239.476M | -186.479M | -87.006M | -61.879M |
| Change In Cash | 263.763M | 28.182M | 191.996M | 59.458M |
| Begin Period Cash Flow | 295.349M | 267.167M | 75.171M | 15.713M |
| End Period Cash Flow | 559.112M | 295.349M | 267.167M | 75.171M |
| Total Cash From Operating Activities | -83.524M | -158.614M | -45.399M | -57.042M |
| Depreciation | 11.756M | 8.405M | 4.442M | 2.489M |
| Other Cashflows From Investing Activities | - | - | 0.595M | 0.595M |
| Dividends Paid | - | - | - | - |
| Change To Inventory | - | 7.835M | 4.357M | - |
| Sale Purchase Of Stock | - | 471.338M | - | - |
| Other Cashflows From Financing Activities | 10.724M | 8.437M | 246.212M | 131.593M |
| Capital Expenditures | 37.359M | 39.798M | 6.735M | 3.91M |
| Change In Working Capital | 104.921M | -0.306M | 30.834M | 0.408M |
| Other Non Cash Items | 11.366M | 4.097M | 0.282M | -0.499M |
| Free Cash Flow | -120.883M | -198.412M | -52.134M | -60.952M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Scottish Mortgage Ord | 2 years ago | 15997051 |
| 2. | ARK Innovation ETF | 2 years ago | 14586941 |
| 3. | ARK Disruptive Innovation Full Composite | 2 years ago | 14109943 |
| 4. | ARK Genomic Revolution ETF | 2 years ago | 9203099 |
| 5. | ARK Genomic Revolution | 2 years ago | 8679480 |
| 6. | SPDR® S&P Biotech ETF | 2 years ago | 6362738 |
| 7. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 5308212 |
| 8. | Nikko AM ARK Disruptive Innovation A USD | 2 years ago | 5076339 |
| 9. | Vanguard Small Cap Index | 2 years ago | 4236679 |
| 10. | Nikko AM ARK Pstv Chg Innovt P JPY Acc | 2 years ago | 3854742 |
| 11. | Vanguard US Growth Investor | 2 years ago | 3591730 |
| 12. | Baillie Gifford US Equity Growth | 2 years ago | 3591730 |
| 13. | iShares Russell 2000 ETF | 2 years ago | 3239193 |
| 14. | Fidelity Contrafund | 2 years ago | 2432845 |
| 15. | Vanguard Small Cap Growth Index Inv | 2 years ago | 2394768 |
| 16. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 2367575 |
| 17. | Fidelity Growth Compy Commingled Pl O | 2 years ago | 1883077 |
| 18. | Baillie Gifford American B Inc | 2 years ago | 1830579 |
| 19. | CS (Lux) Digital Health Equity SB USD | 2 years ago | 1700000 |
| 20. | Fidelity Growth Company Fund | 2 years ago | 1445680 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | ARK Investment Management LLC | 2 years ago | 24587561 |
| 2. | Baillie Gifford & Co Limited. | 2 years ago | 24067804 |
| 3. | Vanguard Group Inc | 2 years ago | 16014764 |
| 4. | Mubadala Investment Company PJSC | 2 years ago | 12985927 |
| 5. | BlackRock Inc | 2 years ago | 12393872 |
| 6. | State Street Corporation | 2 years ago | 12151646 |
| 7. | FMR Inc | 2 years ago | 10897287 |
| 8. | Nikko Asset Management Americas Inc | 2 years ago | 10362803 |
| 9. | Sumitomo Mitsui Trust Holdings Inc | 2 years ago | 10362803 |
| 10. | MIC Capital Management UK LLP | 2 years ago | 8451758 |
| 11. | NVIDIA Corp | 2 years ago | 7706363 |
| 12. | Data Collective IV GP, LLC | 2 years ago | 5941120 |
| 13. | DCVC Opportunity Fund II GP, LLC | 2 years ago | 3951141 |
| 14. | NORGES BANK | 2 years ago | 3531964 |
| 15. | Geode Capital Management, LLC | 2 years ago | 3325985 |
| 16. | Morgan Stanley - Brokerage Accounts | 2 years ago | 2575899 |
| 17. | Goldman Sachs Group Inc | 2 years ago | 2383610 |
| 18. | Junked Platinum Investment Management Ltd | 2 years ago | 2273964 |
| 19. | Dimensional Fund Advisors, Inc. | 2 years ago | 2095000 |
| 20. | Credit Suisse First Boston (CSFB) | 2 years ago | 1936970 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...